Mayo Clinic | Strategic Alliance Partners

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss 2-year follow-up data for liso-cel in relapsed/refractory follicular lymphoma.

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss CD19 expression and the use of tafasitamab in relapsed/refractory DLBCL.

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss their clinical practice experience using tafasitamab in relapsed/refractory DLBCL.

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss data for tafasitamab in relapsed/refractory follicular lymphoma.

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, highlight key data in CML and ALL presented at the 2024 ASH Annual Meeting.

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, detail factors for selecting a TKI in later lines of therapy in chronic myeloid leukemia.

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss data for ponatinib plus chemotherapy in Ph-positive ALL.

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss dosing strategies for ponatinib in CML and ALL.

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the mutational analysis for ponatinib in the OPTIC trial in CP-CML.

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss 5-year data for ponatinib in pretreated CP-CML.

Dr Dronca discusses the FDA approval of subcutaneous nivolumab and hyaluronidase for advanced or metastatic solid tumors.

Yousef Zakharia, MD, spotlights findings from 3 key trials informing the use of standard IO/TKI regimens in metastatic clear cell renal cell carcinoma.

Findings will help identify patients with breast, ovarian, pancreatic, or prostate cancer who may benefit from targeted therapies.

Roxana S. Dronca, MD, discusses the FDA approval of subcutaneous nivolumab across solid tumor indications.

Naseema Gangat, MBBS, discusses the role of rusfertide for decreasing phlebotomy needs and the potential future for disease-modifying PV management.

Naseema Gangat, MBBS, discusses clinical factors that she uses to choose the optimal JAK inhibitors for individual patients with myelofibrosis.

A Mayo Clinic “lifer” who did not consider medicine as a career path until his later teenage years grew into a powerhouse who touched nearly every aspect of the multiple myeloma field, and he continues to push the boundaries of what is possible.

Felipe Batalini, MD, and Alberto Montero, MD, MBA, CPHQ, detail how allosteric inhibitors targeting PIK3CA such as STX-478 may reduce toxicities seen with orthosteric inhibitors.

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, break down the current treatment landscape for relapsed/refractory follicular lymphoma.

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.

A new treatment is showing promise for people with high-risk smoldering multiple myeloma

S. Vincent Rajkumar, MD, of Mayo Clinic; Nosha Farhadfar, MD, of Methodist Physician Practices; and Sonali Smith, MD, of University of Chicago Medicine, sit down with Chandler Park, MD, FACP, to discuss the latest in multiple myeloma, graft-vs-host disease, and non-Hodgkin lymphoma, respectively, from the 2024 ASH Annual Meeting.

Shaji Kumar, MD, discusses notable therapy considerations for multiple myeloma following the 2024/early 2025 NCCN guidelines update.

Shaji Kumar, MD, discusses 2024 updates made to the NCCN guidelines for multiple myeloma treatment, as well as the first 2025 updates.

Tanios S. Bekaii-Saab, MD, discusses the role of liquid biopsies and ctDNA in gastrointestinal cancers.

Tanios S. Bekaii-Saab, MD, discusses the evolution of frontline treatment in advanced pancreatic cancer.

Shaji Kumar, MD, details key updates/revisions made to the multiple myeloma NCCN guidelines in 2024 and the first version of the 2025 guidelines.

Tanios S. Bekaii-Saab, MD, discusses the evolving role of RAS-targeted therapies in pancreatic cancer and where future research in the field may be headed.

Grzegorz S. Nowakowski, MD, discusses the potential implications of the TakeAim Lymphoma trial of emavusertib plus ibrutinib in patients with PCNSL.